Outcome of hispanic patients treated with thrombolytic therapy for acute myocardial infarction Results from the GUSTO-I and -III trials by Cohen, Mauricio G et al.
Outcome of Hispanic Patients
Treated With Thrombolytic
Therapy for Acute Myocardial Infarction
Results from the GUSTO-I and -III Trials
Mauricio G. Cohen, MD, Christopher B. Granger, MD, E. Magnus Ohman, MD,
Amanda L. Stebbins, MS, Liliana R. Grinfeld, MD,* Arturo M. Cagide, MD,* Marcelo V. Elizari, MD,†
Amadeo Betriu, MD,‡ David F. Kong, MD, Eric J. Topol, MD,§ Robert M. Califf, MD
Durham, North Carolina; Buenos Aires, Argentina; Barcelona, Spain; and Cleveland, Ohio
OBJECTIVES We sought to describe the differences in the process of care and clinical outcomes between
Hispanics and non-Hispanics receiving thrombolytic therapy for myocardial infarction (MI).
BACKGROUND Hispanics are the fastest growing and second largest minority in the U.S. but most
cardiovascular disease data on Hispanics has been derived from retrospective studies and vital
statistics. Despite their higher cardiovascular risk-factor profile, better outcomes after MI
have been reported in Hispanics.
METHODS We studied the baseline characteristics, resource use and outcomes of 734 Hispanics and
27,054 non-Hispanics treated for MI in the GUSTO-I and -III trials. The primary end point
of both trials was 30-day mortality.
RESULTS Hispanics were younger, shorter, lighter and more often diabetic and began thrombolysis
9 min later, compared with non-Hispanics. Measures of socioeconomic status (educational
level, employment and health insurance) were lower among Hispanics. Fewer Hispanics than
non-Hispanics underwent in-hospital angiography (70% vs. 74%, p 5 0.013) or bypass
surgery (11% vs. 13.5%, p 5 0.04). Hispanics received more angiotensin-converting enzyme
(ACE) inhibitors and less calcium-channel blockers, prophylactic lidocaine and inotropic
agents. Mortality at 30 days and at one year did not differ significantly between Hispanics and
non-Hispanics (6.4% vs. 6.7% and 9.0% vs. 9.7%, respectively). We noted no interactions
between thrombolytic strategy and Hispanic status on major outcomes (30-day death, stroke
and major bleeding).
CONCLUSIONS The care of Hispanics with MI differed slightly from that of non-Hispanics. Nevertheless,
these differences in care did not affect long-term outcomes. (J Am Coll Cardiol 1999;34:
1729–37) © 1999 by the American College of Cardiology
The Hispanic population is the fastest-growing minority in
the U.S. Hispanics are projected to become the largest
minority by the year 2005, with an estimated population of
over 31 million (about 12% of the total population) (1).
However, the term Hispanic, used exclusively in the U.S.,
was coined without a scientific basis by the Office of
Management and Budget in 1978, to standardize data
collection and publication among federal agencies (2).
Hispanics are a conglomerate of different cultures and
nationalities; their origins are diverse, and they may be of
any race.
Most data on cardiovascular disease prevalence, morbidity
and mortality in Hispanics come from vital statistics (3–8),
retrospective analysis (9), surveillance programs in areas
with large Hispanic population (10), household sampling
(11) and case-control studies (12). Investigations have
shown a higher prevalence of cardiovascular risk factors in
Hispanics compared with non-Hispanics, including diabe-
tes (13–15), central obesity (13,16) and a less favorable lipid
profile (6,9,17). In addition, socioeconomic factors such as
poverty and limited access to health care may unfavorably
influence Hispanics’ morbidity and mortality (18,19).
Two contradictory studies (20,21) have prospectively
evaluated Hispanics with myocardial infarction (MI). Tay-
lor et al. (20) reported a trend toward better outcomes for
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Hispanics compared with blacks and non-Hispanic whites,
even though the known coronary risk factors were more
prevalent in Hispanics. On the other hand, Canto et al. (21)
found no significant in-hospital mortality differences be-
tween Hispanics and non-Hispanic whites.
The large databases of the Global Utilization of Strep-
tokinase and TPA (alteplase) for Occluded Coronary Ar-
teries (GUSTO-I) and Global Use of Strategies to Open
Occluded Coronary Arteries (GUSTO-III) trials allowed us
to maximize the power to detect differences between His-
panics and non-Hispanics and to observe outcomes over a
seven-year period with all currently-used thrombolytic
agents (streptokinase, alteplase and reteplase). We also
determined the resource use and process of care for these
two groups.
METHODS
Patients. The GUSTO-I and GUSTO-III trials have been
described in detail (22,23). These studies enrolled a total of
27,788 patients in the U.S. Briefly, the entry criteria
included patients with ,6 h of typical symptoms of MI and
ST-segment elevation. Patients were randomly allocated to
different thrombolytic strategies according to the trial pro-
tocols. GUSTO-I randomized patients to one of four
thrombolytic regimens: streptokinase with subcutaneous
heparin, streptokinase with intravenous heparin, accelerated
alteplase with intravenous heparin, or a combination of
streptokinase plus alteplase with intravenous heparin.
GUSTO-III compared reteplase with alteplase, with ad-
junctive aspirin and intravenous heparin in both arms.
Informed consent was obtained from all patients, and the
protocols were approved by the institutional review board at
each hospital. The primary end point of both trials was
all-cause, 30-day mortality. One-year mortality was a sec-
ondary end point.
Information on the study patients was prospectively
collected with case-report forms that captured demographic
and clinical characteristics at enrollment and during hospi-
talization up to discharge. Data on patients who were
transferred to another hospital were also collected until
discharge from that hospital. Deaths within 30 days and one
year after enrollment were ascertained by postcards returned
by the patients’ families, through telephone contact or via
registered mail.
Data on the availability of cardiac catheterization facilities
were obtained from the site-descriptor database for the 366
hospitals that participated in both trials.
Hispanic ethnicity. The U.S. Census Bureau considers a
Hispanic to be any person who classifies himself or herself
in one of these origin categories: Mexican, Puerto Rican,
Cuban or other Spanish/Hispanic origin (24). Hispanics
may be of any race. In this study, Hispanic ethnic origin was
determined from the initial patient history and exam by
study investigators, as recorded in source documents. Only
patients enrolled in the U.S. were considered for this
analysis, because interpretations of Hispanic ethnicity may
not be uniform worldwide, and nations may vary in their use
of resources to treat MI (25,26).
Statistical analyses. Continuous variables are presented as
mean 6 SD, and medians are given with 25th and 75th
percentiles. Discrete variables are expressed as frequencies
with percentages. Differences in continuous variables be-
tween groups were tested using the Wilcoxon rank-sum
test. Differences in discrete variables were examined with
chi-square tests. All significance tests were two-tailed.
Results were interpreted as statistically significant when p ,
0.05. Multivariable logistic regression analysis was used to
assess any independent association between Hispanic eth-
nicity and survival, based on a multivariable survival model
from the GUSTO-I population (27). Logistic modeling
also was used to determine any interaction between throm-
bolytic strategy and Hispanic ethnicity. Mortality differ-
ences at one year were assessed using the log-rank test.
As these analyses are multiple, retrospective comparisons,
they should be considered hypothesis-generating rather
than definitive.
RESULTS
Patient characteristics. Of the 27,788 U.S. patients en-
rolled in GUSTO-I and -III, 734 (2.64%) were Hispanic.
The geographic distribution of the Hispanic cohort paral-
leled the national Hispanic distribution reported by the U.S.
Census Bureau (24). High proportions of Hispanics
(86.1%) were enrolled in four regions: 32.8% in the South-
west, 21.5% in the Northeast, 16.8% in the West and 15%
in the South Atlantic (Table 1). Compared with non-
Hispanics, Hispanics were more often treated at hospitals
without cardiac catheterization laboratories (9.3% vs. 13.5%,
p 5 0.09).
Baseline characteristics of the Hispanic populations were
similar between trials. For hypercholesterolemia, systolic
blood pressure, history of smoking and time from symptom
onset to treatment, clinically small differences were statisti-
cally significant (Table 2). Overall, Hispanics tended to be
younger, shorter and weigh less than non-Hispanics. His-
panics were more likely to be diabetic and less likely to have
known elevated cholesterol. More Hispanics presented with
an anterior MI than non-Hispanics (43.3% vs. 38.4%, p 5
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
aPTT 5 activated partial thromboplastin time
GUSTO-I 5 Global Utilization of Streptokinase and
TPA (alteplase) for Occluded Coronary
Arteries
GUSTO-III 5 Global Use of Strategies To Open
Occluded Coronary Arteries
MI 5 myocardial infarction
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0.007). Other baseline characteristics did not differ substan-
tially.
Socioeconomic data. Socioeconomic information was col-
lected in the GUSTO-III trial (Table 3). Fewer Hispanics
finished high school (46.9% vs. 72.7%, p 5 0.001) or college
(15.5% vs. 28.6%, p 5 0.005). Hispanics were less likely to
have private insurance (43.4% vs. 62.6%, p 5 0.001) and
were more likely to be uninsured (18% vs. 6.5%, p 5 0.001)
than non-Hispanics. Hispanics were more often employed
as laborers and less often in management positions. Finally,
Hispanics were less likely to live alone (9.8% vs. 19.3%, p 5
0.008).
Time to treatment. Both time from symptom onset to
presentation and time from presentation to treatment were
longer for Hispanics versus non-Hispanics (Table 4). His-
panics arrived at the hospital a median 5 min later than
non-Hispanics after symptom onset. Once in the hospital,
the time to treatment was 4 min longer for Hispanics than
for non-Hispanics (p 5 0.019). Of note was that 25% of
Hispanics had a time to treatment that was 18 min longer
than that of non-Hispanics.
Use of cardiac medications. The use of cardiac medica-
tions differed slightly between Hispanics and non-Hispanics
(Table 5). During hospitalization, Hispanics patients were
Table 1. Hispanic Enrollment by Region
GUSTO-I GUSTO-III Combined
Southwest (AZ, CO, ID, KS, MT, NM, TX, UT, WY) 207 (33.8%) 34 (27.9%) 241 (32.8%)
Northeast (CT, MA, ME, NH, NY, RI, VT) 124 (20.3%) 34 (27.9%) 158 (21.5%)
West (AK, CA, HI, NV, OR, WA) 98 (16.0%) 25 (20.5%) 123 (16.8%)
Southeast (FL, NC, SC, VA) 106 (17.3%) 4 (3.3%) 110 (15.0%)
Mid-Atlantic (DC, DE, MD, NJ, PA, WV) 30 (4.9%) 8 (6.6%) 38 (5.2%)
Midwest (IA, IL, MN, MO, NE, ND, SD, WI) 22 (3.6%) 8 (6.6%) 30 (4.1%)
Great Lakes (IN, KY, MI, OH) 17 (2.8%) 9 (7.4%) 26 (3.5%)
Mid-South (AL, AR, GA, LA MS, OK, TN) 8 (1.3%) 0 (0.0%) 8 (1.1%)
Table 2. Baseline Clinical Characteristics
GUSTO-I GUSTO-III
Total Hispanics Non-HispanicsHispanics
(n 5 612)
Hispanics
(n 5 122) (n 5 734) (27,054)
Median age (yr) 58.6 (49.9, 66.7) 57.4 (50.6, 66.7) 58.5 (50.2, 66.7) 61.2 (51.5, 70.1)
Male sex 73.6% 73.8% 73.7% 72.3%
Median height (cm) 167.6 (160, 172.7) 167 (160, 173) 167.6 (160, 172.7) 172.7 (165.1, 180)
Median height (kg) 75.5 (68, 86.1) 78.2 (69, 88) 76.8 (68, 86.3) 81 (70.4, 91)
Hypertension 44.9% 41.0% 44.2% 43%
Diabetes 26.4% 24.6% 26.1% 16.6%
Hypercholesterolemia 31.5% 47.9%* 34.3% 38.7%
Current smoker 43.9% 46.7% 44.3% 43.3%
Prior infarction 16.4% 12.3% 15.7% 17.4%
Prior angina 32.0% 40.2% 33.3% 36.1%
Prior angioplasty 5.4% 8.2% 5.9% 6.3%
Prior bypass surgery 3.1% 3.3% 3.1% 5.7%
Systolic BP (mm Hg) 128 (111, 146) 133.5 (120, 150)* 130 (112, 147) 128 (111, 144)
Diastolic BP (mm Hg) 78 (67, 89) 80 (70, 90) 79 (68, 89) 77 (67, 88)
Median heart rate (bpm) 75 (64, 89) 78 (66, 88) 75 (64, 88) 74 (63, 86)
Killip class
I 87.9% 87.7% 87.9% 87.8%
II 10.1% 45.1% 10.5% 10.4%
III 1.2% 0% 0.96% 1.0%
IV 0.83% 2.5% 0.69% 0.76%
Location of infarction
Anterior 41.5% 52.5% 43.3% 38.4%
Inferior 55.2% 45.1% 53.5% 58.5%
Other 2.9% 2.5% 2.9% 2.8%
None 0.33% 0% 0.27% 0.26%
Time from symptom onset to treatment (h) 168 (125, 253) 139 (90, 217) 165 (118, 240) 156 (112, 222)
Data presented are median (25th, 75th percentiles) or percentages. BP 5 blood pressure. *p , 0.05.
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more likely to receive angiotensin-converting enzyme
(ACE) inhibitors and less likely to receive prophylactic
lidocaine, positive inotropic agents and calcium-channel
blockers than non-Hispanics. Discharge prescriptions fol-
lowed a similar pattern, with Hispanics receiving more
ACE inhibitors and nitrates and less digitalis and calcium-
channel blockers than non-Hispanics.
Resource use. Hispanic patients received less invasive
treatment (Table 6). Significantly fewer Hispanics under-
went angiography during hospitalization (69% vs. 73%, p 5
0.013), even after excluding patients enrolled in the
GUSTO-I Angiographic Substudy (68.7% vs. 72.9%, p 5
0.013) (28). The extent of coronary disease differed signif-
icantly between Hispanics and non-Hispanics, however.
Hispanics less often had two-vessel disease compared with
non-Hispanics, but the presence of one- or three-vessel
disease was similar. There were no significant differences in
left ventricular ejection fraction between groups. Despite
the difference in the use of angiography, Hispanics and
non-Hispanics were equally likely to undergo subsequent
angioplasty (30.3% vs. 29.3%, p 5 0.69). Fewer Hispanics,
however, underwent bypass surgery (11% vs. 13.5%, p 5
0.04).
The duration of critical care unit stay (median 3.5 days)
and hospitalization (median 8 days) was identical for both
groups. The use of other cardiac procedures in the acute
coronary unit differed between Hispanics and non-
Hispanics. Fewer Hispanics had a temporary transvenous
pacemaker inserted (6% vs. 9.2%, p 5 0.003), a pulmonary-
artery catheter placed (14.1% vs. 17.7%, p 5 0.01) or
mechanical ventilation (11.6% vs. 15.4%, p 5 0.005),
probably reflecting their lower rate of bypass surgery. The
use of intraaortic balloon pumps was similar in both groups
(4.9% vs. 6.2%, p 5 0.2).
Major clinical outcomes. Unadjusted mortality at 30 days
did not differ significantly between groups (Table 7). Adding
Table 3. Socioeconomic Information from GUSTO-III
Hispanics Non-Hispanics
p Value(n 5 122) (n 5 4,613)
Insurance status
Private 43.4% 62.6% 0.001
Public 38.5% 38.7% 0.966
Other 7.4% 2.2% 0.001
Uninsured 18.0% 6.5% 0.001
Median years of education 12 (8, 12) 12 (12, 14) , 0.001
Completed high school 46.9% 72.7% 0.001
Completed college 15.5% 28.6% 0.005
Primary past or current occupation
Clerical 10.8% 19.7% 0.001
Craftsmen 5.4% 8.7%
Homemaker 15.3% 10.1%
Laborer 55.9% 35.6%
Management 12.6% 25.9%
Substance or alcohol abuse 9.9% 7.1% 0.231
Lives alone 9.8% 19.3% 0.007
Data presented are median (25th, 75th percentiles) or percentages.
Table 4. Time to Treatment
Hispanics Non-Hispanics
p Value(n 5 734) (n 5 27,054)
Symptom onset to hospital arrival, min
Median (25th, 75th percentiles) 90 (58, 148) 85 (54, 138) 0.065
Mean 6 SD 110 6 74 106 6 75
Hospital arrival to treatment, min
Median (25th, 75th percentiles) 68 (48, 99) 64 (46, 91) 0.019
Mean 6 SD 82 6 59 79 6 62
Symptom onset to treatment, min
Median (25th, 75th percentiles) 165 (118, 240) 156 (112, 222) 0.003
Mean 6 SD 185 6 91 176 6 87
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Hispanic ethnicity to the GUSTO-I mortality model did not
increase the model’s ability to predict death at 30 days.
Therefore, even after statistical adjustments for age, gender,
pulse, blood pressure and Killip class, the difference in 30-day
mortality was not significant between groups (odds ratio 1.24;
95% confidence interval, 0.89 to 1.73, p 5 0.21). Unadjusted
1-yr mortality did not differ significantly between Hispanics
and non-Hispanics (9.03% vs. 9.74%, p 5 0.51).
The rates of stroke (hemorrhagic and ischemic) were
similar for both groups, as were the rates of moderate or
severe bleeding (Table 7). The median activated partial
thromboplastin time (aPTT) at 12 h was significantly
higher in Hispanics (73.8 vs. 66.7 s, p # 0.01) but still
within the 50- to 75-s target therapeutic range specified by
the protocols in both groups. Other clinical outcomes,
including recurrent ischemia, congestive heart failure and
cardiogenic shock were similar among Hispanics and non-
Hispanics (Table 7).
No interactions were found between thrombolytic strat-
egy and Hispanic ethnicity on major adverse outcomes
including 30-day death, stroke, cardiogenic shock and
severe bleeding. However, the rates of these outcomes
Table 5. Use of Cardiac Medications
Hispanics Non-Hispanics
p Value(n 5 734) (n 5 27,054)
In-hospital
Beta-blocker
Oral 76.5% 75.2% 0.42
Intravenous 53.8% 51.2% 0.16
Prophylactic lidocaine 15.9% 22.0% , 0.001
Calcium-channel blocker 33.8% 36.9% 0.09
Positive inotropic agents
Digitalis 15.4% 17.0% 0.28
Other 17.0% 23.1% , 0.001
Nitrate
Oral and/or topical 73.9% 75.3% 0.40
Intravenous 87.3% 86.4% 0.52
ACE inhibitor 27.9% 23.7% 0.01
At discharge
Beta-blocker 60.2% 57.9% 0.25
Digitalis 9.8% 13.2% 0.01
Calcium-channel blocker 22.6% 26.3% 0.03
Nitrate 48.7% 45.5% 0.11
ACE inhibitor 20.9% 18.4% 0.11
ACE 5 angiotensin-converting enzyme.
Table 6. Use of Cardiac Procedures
Hispanics Non-Hispanics
p Value(n 5 734) (n 5 27,054)
Procedures
Angiography 69.9% 73.8% 0.013
Angioplasty 29.7% 28.9% NS
Bypass surgery 11.0% 13.5% 0.04
Intraaortic balloon pump 4.9% 6.2% NS
Characteristics of angiography
Elective 90.6% 89.9% NS
Diseased coronary vessels , 0.001
0 12.8% 7.9%
1 46.4% 45.0%
2 21.7% 28.5%
3 19.0% 18.7%
Left ventricular ejection
fraction (%)
50 (40, 60) 50 (40, 61) NS
Data presented are median (25th, 75th percentiles) or percentages. NS 5 not significant.
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tended to be higher for patients treated with streptokinase
compared with those treated with alteplase or reteplase
(Table 8).
DISCUSSION
This study explored the outcomes of 734 Hispanic patients
treated with thrombolytic therapy for acute MI. The find-
ings suggest differences in both the process of care and
resource use for the fastest-growing minority in the U.S.
Despite these differences, however, 30-day and one-year
outcomes were similar to those of other patients treated in
the two GUSTO trials.
Hispanics showed slightly lower in-hospital, 30-day and
one-year unadjusted mortality rates, probably reflecting
their younger age, the strongest predictor of survival. The
mortality differences between Hispanic and non-Hispanics
were not significant. The differences in the process of care of
Hispanics during hospitalization did not affect long-term
mortality. After adjustment for baseline predictors of 30-day
mortality in the GUSTO population (27), there was a trend
towards increased mortality among Hispanics. Of note, the
effect of the thrombolytic strategies on outcomes followed
the same patterns seen in the parent GUSTO-I and
GUSTO-III studies.
Results of previous studies are contradictory regarding
mortality after MI in Hispanics. A prospective study of
outcomes after MI in 147 Hispanics, 2,564 whites and 174
blacks reported a trend towards decreased mortality among
Hispanics (20). An analysis of the second National Registry
of Myocardial Infarction found no significant differences in
in-hospital mortality between non-Hispanic whites and the
largest cohort of Hispanics with MI (21). In an age-specific
analysis, Hispanics less than 40 years old had a mortality risk
four times higher than non-Hispanic whites. These results
must be interpreted cautiously, because patients under 40
years old represented only 4% of that study’s population.
Goff et al. (10) reported increased mortality after MI among
Mexican-Americans compared with non-Hispanic whites.
This study was confounded by a retrospective design and the
use of ICD-9 codes to classify MI discharge diagnoses as
possible or definite.
Other reports based on vital statistics have shown lower
heart-disease mortality among Hispanics (3–7,9). The lim-
Table 7. Major Clinical Outcomes
Hispanics Non-Hispanics
p Value(n 5 734) (n 5 27,054)
In-hospital mortality 5.9% 6.4% 0.59
30-day mortality 6.4% 6.7% 0.91
1-year mortality 9.0% 9.7% 0.51
Any stroke 1.5% 1.6% p
Intracerebral hemorrhage 0.68% 0.74%
Non-hemorrhagic stroke 0.68% 0.72%
Hemorrhagic conversion 0.14% 0.09%
Bleeding
Moderate 12.9% 13.0%
Severe 1.1% 1.4%
Other outcomes
Reinfarction 3.8% 3.7%
Recurrent ischemia 23.7% 23.3%
Congestive heart failure 17.2% 17.7%
Cardiogenic shock 6.4% 6.6%
*p values for stroke, bleeding, and other outcomes were not significant.
Table 8. Outcomes by Thrombolytic Treatment
Alteplase Streptokinase Reteplase
Hispanic Non-Hispanic Hispanic Non-Hispanic Hispanic Non-Hispanic
(n 5 193) (n 5 7,197) (n 5 304) (n 5 10,979) (n 5 84) (n 5 3,158)
30-day mortality 4.2% 6.0% 7.0% 7.0% 3.6% 6.6%
Cardiogenic shock 7.3% 5.5% 5.3% 7.7% 6.0% 5.0%
Stroke 1.0% 1.7% 2.6% 1.3% 1.2% 1.7%
Hemorrhagic stroke 1.0% 0.7% 0.99% 0.47% 0% 1.1%
Severe hemorrhage 1.0% 1.2% 0.99% 1.5% 1.2% 1.4%
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itations of vital statistics include misclassification of His-
panic ethnicity and underestimation of Hispanic deaths in
national death registries (28). Definitions of Hispanic eth-
nicity are not uniform across studies; they can be based on
patient preference, death certificates, medical records, His-
panic surnames, algorithms or responses to national census
questions. These methods are less reliable than those of
randomized trials, where all patients are enrolled based on
prospectively defined inclusion criteria.
Previous investigations have compared the outcomes of
Hispanics versus non-Hispanic whites and blacks, catego-
rizing Hispanics as a racial group. In this study, we
differentiated by ethnicity rather than race; as a result, we
compared the outcomes of Hispanics treated for MI with
the rest of the study patients (non-Hispanics). For this
reason, we purposely did not identify other racial minorities
in the comparisons.
The high prevalence of diabetes among Hispanics com-
pared with non-Hispanics in our study agrees with previous
observational studies (13–15). However, other risk factors,
including known hypercholesterolemia, hypertension and
cigarette smoking did not follow observed patterns
(13,17,29). This may reflect a lower ascertainment of
hypertension and hypercholesterolemia in Hispanics, who
are less likely to regularly visit a physician (30). Interest-
ingly, Hispanics were more likely to present with anterior
infarction than non-Hispanics. This has been observed in
the Thrombolysis In Myocardial Infarction (TIMI)-II study
(20) and the second National Registry of Myocardial In-
farction (21).
Time to treatment. Time from symptom onset to throm-
bolytic therapy was longer in Hispanics than in non-
Hispanics. This difference was mainly at the expense of a
longer presentation delay, which reflects patient-related
delays. Several factors, including cultural differences in the
perceptions of disease, less comprehensive health-insurance
coverage, access to care and educational level (18,31) may
have influenced the decision to seek medical care among
Hispanics. Clark et al. (32) studied inner-city patients with
suspected MI and showed longer prehospital delays for
Hispanics than non-Hispanic whites. Most of these delays
were attributed to the time needed for patients to decide to
seek medical care after symptom onset (32). One study has
shown that Hispanics tend to underuse emergency medical
systems (21). The GUSTO studies did not ascertain use of
ambulance services. The influence of household members in
the delay in seeking medical attention remains unclear.
Alonzo et al. (33) reported increased prehospital delays
when the decision to call was given to a family member. We
found that Hispanics were less likely than non-Hispanics to
live alone.
The in-hospital component of treatment delay, the
“door-to-needle” time, was also longer among Hispanics.
Language barriers and interpretation of the informed con-
sent for enrollment in a clinical trial may have contributed to
these delays. The differences in treatment delays in
GUSTO-III compared with GUSTO-I do show that
changes in the health-care system over the last five years to
reduce delays in patients with MI also have included the
Hispanic minority.
Angiography and revascularization. Although a high pro-
portion of Hispanics (70%) underwent angiography, this
rate was 4% lower than for non-Hispanics (74%). Younger
age and recurrent ischemia are strong predictors of the use
of angiography (34). We expected that Hispanics would
undergo angiography at least as often as non-Hispanics
because of their younger age and similar incidence of
post-MI ischemic complications. On the other hand, His-
panics tended to seek medical care in hospitals without
cardiac catheterization facilities, which are a negative pre-
dictor for the use of angiography in post-MI patients (34).
Studies have reported similar findings on the use of invasive
cardiac procedures (35). In a report from the Corpus Christi
Heart Project, Mexican-Americans admitted for MI were
catheterized 7% less often than non-Hispanic whites. How-
ever, the 52% rate of angiography in that investigation was
substantially lower than it was in this study (36). Our
findings contrast with those of Canto et al. (21), who
showed that Hispanics more often went to hospitals with
catheterization facilities and were as likely as non-Hispanic
whites to have invasive procedures.
The extent of coronary disease, an independent predictor
for bypass surgery, was greater in non-Hispanics. Non-
Hispanics had a higher prevalence of two-vessel disease
than Hispanics, whereas the rate of three-vessel disease was
similar in both groups. This difference may have contributed
to the greater use of surgical revascularization in non-
Hispanics, but it is three-vessel (and not two-vessel) disease
that has been correlated with the use of bypass surgery (34).
The rates of single-vessel disease were similar and may
explain the similar use of angioplasty among the two groups.
Other factors that may have influenced the lower use of
angiography and bypass surgery in Hispanics include less
comprehensive insurance coverage (37), cultural perceptions
of invasive procedures or major surgery and educational
level. Schecter et al. (38) reported that coronary care unit
patients with lower educational levels were significantly
more likely to disagree with a physician’s recommendation
to undergo angiography.
The use of cardiac medications during admission and at
discharge also differed between Hispanics and non-
Hispanics. Hispanics were more likely to receive ACE
inhibitors, which are known to reduce mortality after MI. A
higher use of ACE inhibitors among Hispanics also was
observed in a Texas surveillance study (39). Perhaps the
greater prevalence of diabetes among Hispanics led physi-
cians to use ACE inhibitors more often. Non-Hispanics
were more commonly prescribed drugs shown to have no
benefit or even a detrimental effect, such as prophylactic
lidocaine, calcium-channel blockers and inotropic agents.
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These results contrast with other investigations that have
shown lower beta-adrenergic blocking agent use among
Hispanics (21,39).
We measured socioeconomic status by educational level
and occupation in this investigation. The association be-
tween these two variables and all-cause mortality has been
validated in the literature. In general, mortality decreases as
educational level increases. The same pattern also has been
shown for different occupational categories, with laborers
having the highest mortality and professionals, the lowest.
The same association with socioeconomic status has been
seen for cardiovascular mortality (40). Our results indicated
a lower socioeconomic status for Hispanics than for non-
Hispanics, but we did not detect a significant association
with mortality. Other factors that favorably influence out-
comes (such as diet, greater social support and lifestyle) may
interact with indicators of socioeconomic status. Farmer et
al. (41) reported an association between the greater social
support observed among Hispanics and greater survival after
MI.
Study limitations. This analysis is a multiple, retrospective
comparison and is subject to the limitations of this type of
study. In addition, subcategories of Hispanics based on
national origin, such as Mexican, Puerto Rican, Central and
South American or Cuban were, unfortunately, not col-
lected by the case report form. The GUSTO trials consid-
ered patients presenting with a diagnosis of MI who were
candidates for thrombolytic therapy. This may account for
the lower proportion of Hispanics (2.64%) enrolled in the
trial compared with the general population (10.65%). This
lower proportion of Hispanics may reflect: 1) underreported
Hispanic ethnicity, 2) nonuniform enrollment across geo-
graphic regions and urban centers, with higher enrollment
in areas with few Hispanic residents, 3) selective nonenroll-
ment of Hispanics at individual centers, 4) reduced access to
health care, or 5) a lower incidence of MI due to the lower
median age of Hispanics, which is unlikely (42). Finally, the
categorization of Hispanic ethnicity did not follow a specific
algorithm, leaving open the possibility some truly Hispanic
patients were not categorized as such. Out-of-hospital
deaths were not captured by the GUSTO trials.
Conclusions. This study provides detailed information on
short- and long-term mortality and process of care of
Hispanics hospitalized for MI. After adjusting for differ-
ences in baseline characteristics, we noted a trend towards
increased mortality in Hispanics compared with non-
Hispanics. At one-year follow-up, the difference in mortal-
ity was not statistically significant. Different aspects of the
process of care, such as time to thrombolysis and resource
use, show slight but statistically significant differences be-
tween Hispanics and non-Hispanics. Hispanics had a
higher prevalence of diabetes and a lower socioeconomic
status. We observed longer delays in time to hospital arrival
and time to treatment in Hispanics compared with non-
Hispanics. Fewer Hispanics underwent angiography and
bypass surgery, which could reflect lesser insurance coverage
and less severe coronary disease, respectively. Nevertheless,
these differences in care did not affect long-term outcomes.
Public education campaigns directed to Hispanics should
be considered, to reduce patient-related delays in treatment.
To identify possible biases, studies should further explore
access to and processes of health care for Hispanic sub-
groups.
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